TMEM268

Across TCGA pan-cancer cohorts, TMEM268 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TMEM268 data layer compared with 21 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMEM268 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM268 expression acts as an unfavorable survival marker.

HNSC, ESCA, and COAD are the cancer types where TMEM268 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.103	0.697	<.001	36	view →
ESCA	DFS	Median	All	0.080	0.533	<.001	18	view →
COAD	OS	Median	III,IV	0.208	0.791	.008	9	view →
STAD	OS	Median	III,IV	0.184	0.641	.011	9	view →
PRAD	DFS	Median	All	0.085	0.774	.007	6	view →
SKCM	DFS	Median	All	0.046	0.738	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TMEM268–HNSC (DFS)

Open the HNSC breakdown →